A trial of the DESolve bioresorbable scaffold found the device to be effective and safe, with signs of early vessel restoration noted at six months, Dr. Alexandre Abizaid reported at the EuroPCR conference. "I think that bioabsorbable scaffolds are here to stay," Abizaid said. "It's just the tip of a big iceberg, and this is probably going to be the default therapy in the future."

Related Summaries